Summary More accurate criteria are required for the selection of patients with node-negative breast cancer for systemic adjuvant therapy. Expression of epidermal growth factor receptor (EGFr) has been shown previously to be inversely related to oestrogen receptor (ER) in patients with operable breast cancer and to be associated with a poorer prognosis. Analysis of EGFr and ER was performed on tumour samples from 231 patients with operable breast cancer followed for up to 6 years after surgery. The median duration of follow-up in patients still alive at the time of analysis was 45 months. Thirty-five percent of patients (82) The histological status of the axillary lymph nodes, specifically the absolute number of nodes involved, remains the most potent prognostic marker for patients with operable breast cancer (Valagussa et al., 1978; Fisher et al., 1983) . Tumour recurrence and death due to breast cancer, however, affects a significant proportion of patients with node-negative disease (Fisher et al., 1989c) . Recurrence rates of up to 43% and mortality at 10 years of 32% have been reported (Fisher et al., 1989b) , suggesting a need for effective adjuvant systemic therapy for selected patients in this supposedly good prognostic subgroup.
The histological status of the axillary lymph nodes, specifically the absolute number of nodes involved, remains the most potent prognostic marker for patients with operable breast cancer (Valagussa et al., 1978; Fisher et al., 1983) . Tumour recurrence and death due to breast cancer, however, affects a significant proportion of patients with node-negative disease (Fisher et al., 1989c) . Recurrence rates of up to 43% and mortality at 10 years of 32% have been reported (Fisher et al., 1989b) , suggesting a need for effective adjuvant systemic therapy for selected patients in this supposedly good prognostic subgroup.
It is now recognised that there is a need for a marker (or markers) capable of discriminating patients with axillary node-negative disease at high risk of recurrence and death. Tumour oestrogen receptor (ER) content has been proposed but there is disagreement about its value (Cooke et al., 1979; Fisher et al., 1988) . This has been supported by the long term results of large trials evaluating the use of adjuvant tamoxifen for patients with operable breast cancer in which a beneficial effect is shown also in patients with ER negative tumours (Nolvadex Adjuvant Trial Organisation [NATO], 1988) . Although recent trials of systemic adjuvant chemotherapy in patients with axillary node-negative disease and ER negative tumours have shown small but significant benefits in terms of recurrence-free survival, there was no effect on overall survival (Fisher et al., 1989b; Mansour et al., 1989 ; Ludwig breast cancer study group, 1989 ) but this may reflect a relatively short follow-up. In one small trial there was a benefit in terms of overall survival (Bonadonna & Valagussa, 1987) .
There have been several reports describing the presence of specific, high affinity receptors for epidermal growth factor (EGFr) on membranes prepared from primary human breast carcinoma (Sainsbury et al., 1985; Perez et al., 1984) . These studies showed a marked inverse relationship between expression of EGFr and ER. Tumours which overexpressed EGFr were associated with a poor overall prognosis (Sainsbury et al., 1987; Rios et al., 1988 ) but short follow-up precluded close examination of patient subgroups in particular nodenegative patients. Continued prospective patient follow-up and increased patient numbers now allows examination of the prognostic value of EGFr, particularly in node-negative patients.
Patients and methods
Two hundred and thirty-one consecutive patients with operatable breast cancer and without biochemical or radiological evidence of distant metastases were treated by simple mastectomy (n = 181) or wide local excision and post-operative radiotherapy by external beam and iridium wire implants (n = 50). Level I axillary nodes (behind pectoralis major) were sampled if palpable at surgery (n = 129, 56%). An average of four nodes were sampled and for those with positive nodes an average of three contained metastatic tumour (range 1-8). In patients treated by mastectomy adjuvant radiotherapy was given to the ipsilateral axilla if the nodes were involved. No patient received adjuvant chemotherapy in this study. Forty patients towards the end of the study received adjuvant tamoxifen (20 mg daily) following the early results of the NATO study.
The resection specimens were taken immediately to the Department of Pathology on ice. Maximum tumour diameter was recorded and tumour blocks removed for histopathology. Tumour specimens adjacent to the block for histology were stored at -20°C in a sucrose/glycerol medium (Crawford et al., 1984) prior to receptor analysis. EGFr was determined using an I'25-labelled EGF radioreceptor assay with a cut-off value of 10 fmol mg-' protein and ER by the dextran charcoal method with a 5 fmol mg-' cytosol protein cut-off as previously described (Nicholson et al., 1988b) . Histological examination of haematoxylin and eosin stained, formalin fixed, paraffin embedded sections was performed and ductal Correspondence: S. Nicholson. carcinomas graded according to the modified Bloom and Richardson method (Elston et al., 1982) .
Follow-up was conducted every 3 months for the first 18 months, 6 monthly until 3 years and annually thereafter until recurrence had been confirmed radiologically, cytologically or histologically. Follow-up thereafter was every 3 months or less until death. Patients with confirmed recurrent disease were treated according to standard protocols in an advanced medical oncoloy clinic (ALH). Patients with predominantly soft tissue or skeletal disease were treated by endocrine manipulation (tamoxifen if postmenopausal or oophorectomy + tamoxifen if premenopausal). Patients with visceral disease and those who had failed first and second line endocrine therapy were treated with chemotherapy -usually single agent with either mitoxantrone or adriamycin. Patients with isolated soft tissue relapse (axilla or mastectomy flap) usually received radiotherapy in addition to endocrine manipulation.
Statistics
Analysis of patient and tumour characteristics within subgroups was performed using Chi-square contingency tables. Survival data was analysed using the log rank method (Peto et al., 1977) and the Cox proportional hazards regression model (Cox, 1972) .
Results

Relationship of EGFr to other prognostic indicators
Of 231 patients, 213 (92%) had ductal carcinomas. Eightfour patients (36%) were under 50 years of age and 147 (64%) were over 50. Eighty-two patients (35%) had tumours with levels of EGFr> 10 fmol mg-' protein (EGFr positive) and 109 patients (47%) had tumours with a cytosolic ER content >5fmolmg-' (ER positive). There was a marked inverse relationship between EGFr and ER (P <0.00001, Table I ).
In the 213 patients with ductal carcinomas there was a significant association between increasing tumour grade and expression of EGFr (P <0.025, Table II ). There was no relationship between EGFr and axillary node status (Table  III) or tumour size (Table IV) .
Relationship of EGFr to time to relapse and overall survival After a median follow-up of 45 months for patients still alive at the time of analysis, 125 patients (54%) have recurred and (65%) (35%) X' = 40.808, dof = l, P < 0.00001. Figure 2a and b) . Similarly in patients with lower grade tumours (Grades I and II) there was a reduction in recurrence-free and overall survival for those with EGFr positive tumours (Figures 3a and b) .
For patients with ER negative tumours co-expression of EGFr reduced survival (Figure 4a ). There was a similar trend for patients whose tumours contained both EGFr and ER (Figure 4b) (n = 49).
significant variables. In terms of overall surviv node status was significant. In the second analysis (Table VIb) , 121 pat tologically confirmed nodal status were ass( results were similar to the first analysis with status emerging as the most powerful prognos both recurrence-free and overall survival (P = 0.027 and P = 0.002 respectively). EGFr just failed to reach significance in this analysis (P = 0.053 and P = 0.072 respectively). Neither ER, tumour grade nor size were significant factors.
In the third analysis (Table VIc) only patients with axillary node-negative (histologically confirmed), ductal carcinomas (n = 49) were assessed. Both EGFr and tumour size were significant factors for recurrence-free survival but only EGFr was significant for overall survival.
Discussion b 72
This study has emphasised the value of EGFr in selecting a poor prognosis group within a population of patients with 46 operable breast cancer. The findings in the node negative group are potentially of greater importance. The study, however, was conducted between 1983 and 1987 before the worldwide results of adjuvant therapy were collated. During this period it was the policy of many British surgeons to 94) perform only selective node sampling whereas now most authorities would consider node sampling essential. In this paper we have emphasised the analyses where node status 15)
was histologically confirmed in order not to overstate the extent of the findings.
There can be little doubt that patients with involved axillary lymph nodes require adjuvant therapy but debate continues as to the optimum. Systemic adjuvant chemotherapy almost certainly confers a survival advantage in premenopausal patients (Fisher et al., 1986; Bonadonna et al., 1985) but the mechanism of action has been questioned (Padmanabhan et al., 1986 (Fisher et al., t of data for 1989a) showed an advantage in the treated group in terms of disease-free but not overall survival.
These studies suggest that, although ER may be a useful prognostic marker overall (Cooke et al., 1979) and in predicting response to endocrine therapy at relapse (Leake et al., .0005 1981) , it may not be so useful in assigning different patient .059 subgroups to the currently available adjuvant therapies.
Thymidine labelling has been used as a prognostic marker .142 in node-negative disease (Silvestrini et al., 1985) but the technique is complex and time consuming and, therefore, fogical node probably not applicable to routine clinical practice. A recent study (Clark et al., 1989) showed that flow cytometry may offer a practical alternative. In this study disease-free survival .002
for patients with node-negative breast cancer was signifi-.072 cantly worse if their tumours were either aneuploid or diploid with a high S-phase fraction.
Expression of the c-erbB-2 oncoprotein, which can be measured using immunohistochemical staining of formalin gically negative fixed, paraffin embedded sections, has recently been evaluated as a prognostic marker in breast cancer with promising results (Wright et al., 1989) , but its prognostic power may be .026 greatest in node-positive patients (Slamon et al., 1987 ) from whom few clinicians would now withhold adjuvant therapy.
Overexpression of EGFr has been shown previously to be a marker of early relapse and death in patients with operable gically confirmed breast cancer (Sainsbury et al., 1987; Rios et al., 1988) .
negative nodes Overexpression of EGFr in breast tumours of elderly patients treated with primary endocrine therapy was associated with rapid disease progression and poor response rates (Nicholson tal only lymph et al., 1988a) as in patients with recurrent breast cancer after surgical treatment This study has demonstrated that overexpression of EGFr in tumours of patients with operable breast cancer is associated with a poor overall prognosis and that EGFr status is second only to axillary lymph node status in its prognostic power. In subgroups which would otherwise have been considered to have a good prognosis (axillary node-negative and low tumour grade) overexpression of EGFr led to a significant reduction in both relapse-free and overall survival. Similarly, patients whose tumours coexpressed EGFr and ER had survival patterns similar to those expressing EGFr alone, suggesting that overexpression of EGFr conferred a growth potential on a tumour which obviated its requirement for oestrogen. Although the node negative (histologically confirmed) groups was relatively small the magnitude of the differences in this group between those with EGFr negative and positive tumours was great. In a multivariate analysis when clinical node status was assessed the effect of EGFr expression in the node negative group was enhanced (P = 0.01 for relapse-free and overall survival) suggesting that these differences are indeed of practical importance.
These results, together with those which have shown a failure of response to endocrine therapy associated with overexpression, suggest that EGFr may be a clinically useful prognostic marker in patients with axillary node-negative breast cancer capable of identifying a poor prognosis subgroup which may benefit from systemic adjuvant chemotherapy.
